Australia markets close in 3 hours 49 minutes
  • ALL ORDS

    7,753.90
    +63.70 (+0.83%)
     
  • ASX 200

    7,439.50
    +64.60 (+0.88%)
     
  • AUD/USD

    0.7487
    +0.0010 (+0.13%)
     
  • OIL

    82.85
    -0.11 (-0.13%)
     
  • GOLD

    1,771.80
    +1.30 (+0.07%)
     
  • BTC-AUD

    85,785.53
    +2,593.06 (+3.12%)
     
  • CMC Crypto 200

    1,487.21
    +23.85 (+1.63%)
     
  • AUD/EUR

    0.6425
    +0.0005 (+0.07%)
     
  • AUD/NZD

    1.0444
    -0.0003 (-0.03%)
     
  • NZX 50

    13,138.31
    +72.39 (+0.55%)
     
  • NASDAQ

    15,410.72
    +109.83 (+0.72%)
     
  • FTSE

    7,217.53
    +13.70 (+0.19%)
     
  • Dow Jones

    35,457.31
    +198.70 (+0.56%)
     
  • DAX

    15,515.83
    +41.36 (+0.27%)
     
  • Hang Seng

    25,787.21
    +377.46 (+1.49%)
     
  • NIKKEI 225

    29,456.05
    +240.53 (+0.82%)
     

Black Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass. and NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 4:40 PM ET.

A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the presentation will also be available and archived on the site for three weeks.

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of MasterKey therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform and drug discovery engine, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families, and develop a single small molecule therapy that targets a specific family of mutations, termed a MasterKey therapy. Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts
For Investors:
Natalie Wildenradt
investors@bdtx.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtx.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting